NurseJet
Back to Discover
Research ArticleResearch

Ferric citrate met noninferiority criteria for phosphorus reduction during hemodialysis

Renal failure (PubMed)Aug 31, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A Chinese phase III trial found ferric citrate noninferior to sevelamer carbonate for lowering serum phosphorus over 12 weeks.

What NurseJet pulled from the source

The open-label trial randomized 239 patients receiving maintenance hemodialysis. The between-group difference in phosphorus change was −0.09 mmol/L (95% CI −0.24 to 0.05), within the prespecified noninferiority margin of 0.32 mmol/L.

Why this matters for nurses

The findings help nurses interpret phosphorus response and tolerability when caring for patients taking phosphate binders.

Bedside takeaway

When reviewing prescribed binder therapy, communicate phosphorus trends and gastrointestinal symptoms to the dialysis team.

Key takeaways

  • Target phosphorus achievement did not differ significantly between groups.
  • Ferric citrate improved iron-related measures and hemoglobin.
  • Most reported treatment-emergent adverse events were mild; gastrointestinal disorders were the most common.

Practice implications

  • When reviewing prescribed binder therapy, communicate phosphorus trends and gastrointestinal symptoms to the dialysis team.

Limitations & cautions

  • Abstract-only summary. The study was open-label, lasted 12 weeks, and enrolled Chinese patients. It does not establish long-term safety or superiority for patient-centered outcomes.
  • AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Renal failure (PubMed)

Renal failure (PubMed). Efficacy and safety of ferric citrate tablets in Chinese patients with hyperphosphatemia undergoing maintenance hemodialysis: a multicenter, randomized, open-label, active-controlled, phase III trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42675918/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Renal failure (PubMed)

A single-center retrospective cohort found that approximately one quarter of laboratory-defined acute kidney injury cases on internal medicine wards were not documented, particularly when maximal creatinine was lower.

Med-SurgAI summaryReview source

European heart journal (PubMed)

In the pragmatic TARGET-D randomized trial, vitamin D dosing titrated to a serum target did not significantly reduce the composite of death, recurrent myocardial infarction, heart-failure hospitalization, or stroke after myocardial infarction.

TelemetryMed-SurgAI summaryReview source

Journal of the American Medical Directors Association (PubMed)

A prospective Dutch nursing-home cohort found clinically important differences in illness burden across respiratory viruses, with influenza and human metapneumovirus standing out.

GeriatricsMed-SurgAI summaryReview source